Novo Nordisk to cut US list prices for Ozempic and Wegovy

Novo Nordisk announced it will reduce the US list prices for its weight-loss and diabetes drugs Ozempic and Wegovy. The price cuts, which will take effect in 2027, could be as much as 50%. This move addresses growing pressure over the high cost of these popular medications.